Compare HTCR & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTCR | PPCB |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | Japan | Australia |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.6M |
| IPO Year | 2022 | 2011 |
| Metric | HTCR | PPCB |
|---|---|---|
| Price | $1.77 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.1K | ★ 171.2K |
| Earning Date | 11-17-2026 | 09-29-2026 |
| Dividend Yield | ★ 145.25% | N/A |
| EPS Growth | ★ 414.29 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,407,229.00 | N/A |
| Revenue This Year | $118.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.15 | $0.06 |
| 52 Week High | $3.97 | $6.79 |
| Indicator | HTCR | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 29.99 | 34.52 |
| Support Level | N/A | $0.17 |
| Resistance Level | $2.16 | $1.29 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 19.61 | 15.59 |
HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.